000			02273 a2200649 4500
005			20250517122616.0
264		0	_c20180222
008			201802s 0 0 eng d
022			_a1949-2553
024	7		_a10.18632/oncotarget.12822 _2doi
040			_aNLM _beng _cNLM
100	1		_aNi, Chen-Xu
245	0	0	_aWM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway. _h[electronic resource]
260			_bOncotarget _cNov 2016
300			_a79544-79556 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAlkaloids _xpharmacology
650	0	4	_aAnimals
650	0	4	_aAntineoplastic Agents _xpharmacology
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xpharmacology
650	0	4	_aCarcinoma, Hepatocellular _xdrug therapy
650	0	4	_aCell Line, Tumor
650	0	4	_aCell Proliferation _xdrug effects
650	0	4	_aCell Self Renewal _xdrug effects
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDoxorubicin _xpharmacology
650	0	4	_aDrug Resistance, Neoplasm _xdrug effects
650	0	4	_aEpithelial Cell Adhesion Molecule _xgenetics
650	0	4	_aGene Expression Regulation, Neoplastic
650	0	4	_aGlycogen Synthase Kinase 3 beta _xmetabolism
650	0	4	_aHumans
650	0	4	_aInhibitory Concentration 50
650	0	4	_aLiver Neoplasms _xdrug therapy
650	0	4	_aMale
650	0	4	_aMice, Inbred BALB C
650	0	4	_aMice, Nude
650	0	4	_aNeoplastic Stem Cells _xdrug effects
650	0	4	_aPhenotype
650	0	4	_aProto-Oncogene Proteins c-akt _xmetabolism
650	0	4	_aQuinolizines _xpharmacology
650	0	4	_aTime Factors
650	0	4	_aTumor Burden _xdrug effects
650	0	4	_aWnt Signaling Pathway _xdrug effects
650	0	4	_aXenograft Model Antitumor Assays
650	0	4	_abeta Catenin _xmetabolism
700	1		_aQi, Yang
700	1		_aZhang, Jin
700	1		_aLiu, Ying
700	1		_aXu, Wei-Heng
700	1		_aXu, Jing
700	1		_aHu, Hong-Gang
700	1		_aWu, Qiu-Ye
700	1		_aWang, Yan
700	1		_aZhang, Jun-Ping
773	0		_tOncotarget _gvol. 7 _gno. 48 _gp. 79544-79556
856	4	0	_uhttps://doi.org/10.18632/oncotarget.12822 _zAvailable from publisher's website
999			_c26552167 _d26552167